News for IONS Stock

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema Ionis reports second quarter 2025 financial results and highlights progress on key programs TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS) Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice Ionis to hold second quarter 2025 financial results webcast Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026 First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides Ionis to host 2025 virtual Annual Meeting of Stockholders Ionis reports first quarter 2025 financial results New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies Ionis to hold first quarter 2025 financial results webcast Ionis to host expert panel discussion on sHTG Ionis to present at upcoming investor conferences Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. Ionis and Ono announce global license agreement for sapablursen in polycythemia vera WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy Ionis to present at upcoming investor conferences New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control Ionis reports fourth quarter and full year 2024 financial results Ionis to hold fourth quarter and full year 2024 financial results webcast Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet Ionis to present at upcoming investor conferences Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome Ionis reports third quarter 2024 financial results Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE Ionis to hold third quarter 2024 financial results webcast WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease Ionis announces pricing of $500.3 million public offering Ionis announces proposed public offering of common stock Ionis to present at upcoming investor conferences Ionis reports second quarter 2024 financial results Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome Ionis to hold second quarter 2024 financial results webcast Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema Ionis to present at TD Cowen Genetic Medicines & RNA Summit Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema Ionis to hold donidalorsen Phase 3 data webcast New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome Ionis to host 2024 virtual Annual Meeting of Stockholders Ionis reports first quarter 2024 financial results Ionis Publishes 2023 Corporate Responsibility Report Ionis to hold first quarter 2024 financial results webcast Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome Ionis to present at upcoming investor conferences Ionis to hold olezarsen Phase 3 data webcast Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH Ionis announces new chief global product strategy officer to lead next phase of commercial growth Ionis to present at upcoming investor conferences Ionis reports fourth quarter and full year 2023 financial results Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy Ionis to hold fourth quarter and full year 2023 financial results webcast Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen) WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema Ionis announces the appointment of Michael Yang to Board of Directors Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema Ionis to present at upcoming investor conferences Ionis reports third quarter 2023 financial results Ionis to hold third quarter 2023 financial results webcast Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome Ionis to host investor and analyst day event Ionis to present at upcoming investor conferences Ionis reports second quarter 2023 financial results Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America Ionis to hold second quarter 2023 financial results webcast Eplontersen continued to show improvement in ATTRv-PN through 85 weeks Ionis to present at upcoming investor conference New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen) Ionis prices private placement of convertible senior notes Ionis announces proposed private placement of convertible notes Ionis announces positive donidalorsen late-stage clinical progress in HAE Ionis to host 2023 virtual Annual Meeting of Stockholders Ionis to present at upcoming investor conferences Ionis reports first quarter 2023 financial results FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks Ionis to hold first quarter 2023 financial results webcast New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease Ionis to present at upcoming investor conferences Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis to present at upcoming investor conferences Ionis reports fourth quarter and full year 2022 financial results Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting Ionis to hold fourth quarter and full year 2022 financial results webcast Ionis announces GSK has advanced bepirovirsen into Phase 3 development Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness Ionis to present at 41st Annual J.P. Morgan Healthcare conference Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS Ionis partners with Metagenomi to add gene editing to its broad technology platform Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting Ionis to present at upcoming investor conferences Ionis reports third quarter financial results Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022 Ionis announces positive results from fesomersen development program Ionis to hold third quarter 2022 financial results webcast Ionis announces plan for new manufacturing facility in Oceanside, Calif. Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis Ionis to present at upcoming investor conferences Ionis reports second quarter financial results and recent business achievements Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment Ionis to hold second quarter 2022 financial results webcast Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™ Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients Ionis to present at RBC Capital Markets Global Healthcare Conference Ionis reports first quarter financial results and recent business achievements Ionis to host 2022 virtual Annual Meeting of Stockholders Ionis to hold first quarter 2022 financial results webcast Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis Ionis to present at upcoming investor conferences Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine Ionis calls for applications for Janice Wiesman Young Investigator Grant Program Ionis to present at the Cowen Annual Health Care Conference Ionis reports fourth quarter and full year 2021 financial results and recent business achievements Ionis to hold full year 2021 financial results webcast Pfizer and Ionis announce discontinuation of vupanorsen clinical development program Ionis announces eplontersen receives orphan drug designation from U.S. FDA Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial Ionis to present at 40th Annual J.P. Morgan Healthcare conference Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA Ionis and AstraZeneca close deal to develop and commercialize eplontersen Ionis and AstraZeneca to develop and commercialize eplontersen Ionis to hold virtual investor day event Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021 Ionis to present at upcoming virtual investor conferences Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting Ionis reports third quarter 2021 financial results and recent business achievements Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia Ionis to hold third quarter 2021 financial results webcast Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting Ionis to present at upcoming virtual investor conferences Ionis reports second quarter 2021 financial results and recent business achievements Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC Ionis to hold second quarter 2021 financial results webcast Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting Ionis announces changes to its board of directors at annual meeting of stockholders Ionis to present at upcoming investor conferences Ionis to present at upcoming investor conferences Ionis to host 2021 virtual annual meeting of stockholders Ionis reports first quarter 2021 financial results and recent business achievements Ionis to hold first quarter 2021 financial results webcast Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease Ionis prices private placement of convertible senior notes Ionis announces proposed private placement of convertible notes Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema Ionis to present at upcoming investor conferences Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx) Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis Ionis reports fourth quarter and full year 2020 financial results and recent business achievements Ionis to present at upcoming investor conferences Ionis to hold 2020 financial results webcast Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation Ionis highlights achievements, commercial strategy and technology advancements at Investor Day Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome Ionis to hold virtual investor day event Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020 Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020 Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference Ionis to present at upcoming virtual investor conferences WAYLIVRA▼® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in Scotland Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes Ionis reports third quarter 2020 financial results and recent business achievements Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial Ionis to hold third quarter 2020 financial results webcast Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil /C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./ Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA Ionis to present at upcoming virtual investor conferences New England Journal of Medicine publishes study results evaluating Ionis antisense therapy in treatment of patients with hereditary angioedema Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020 Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020 Ionis Pharmaceuticals to hold cardio-renal franchise webcast Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020 Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020 Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany Ionis reports second quarter 2020 financial results and recent business achievements Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast Akcea Appoints New Senior Vice President, Global Medical Affairs Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast Ionis Pharmaceuticals to hold neurology franchise webcast